COMMUNIQUÉS West-GlobeNewswire

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
30/03/2026
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in [...]
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
30/03/2026
Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in [...]
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
30/03/2026
Q4 and FY Revenue of $9.2 million and $38.7 million Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) Q4 and FY [...]
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
30/03/2026
FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision [...]
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
30/03/2026
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement, with a 47.5% [...]
INmune Bio Inc. Announces 2025 Results and Provides Business Update
30/03/2026
Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité
30/03/2026
Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025 Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme 1 au 31 décembre 2025 Réalisation d'une [...]
Terra Pharm Medical Marijuana Organization Opens Cultivation Facility and Dispensaries in Pennsylvania
30/03/2026
Pennsylvania’s newest medical marijuana organization partners with Duquesne University Nasuti College of Osteopathic Medicine on evidence-based research. PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Terra Pharm, [...]
IBA – ACQUISITION D’ACTIONS PROPRES
30/03/2026
Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
IBA – ACQUISITION OF OWN SHARES
30/03/2026
Louvain-la-Neuve, Belgium, March 30 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Children’s National Hospital announces new pain management center to help children and their families reclaim their lives from chronic pain
30/03/2026
Supported by an $8.895 million investment, new center will deliver comprehensive, multidisciplinary care for children and adolescents experiencing acute and chronic pain Washington, DC, March 30, 2026 (GLOBE NEWSWIRE [...]
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
30/03/2026
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an [...]
Grâce à des avancées significatives dans le financement de son projet industriel en France, Carbios confirme son objectif de construction de l’usine de Longlaville.
30/03/2026
Carbios confirme son objectif concernant le projet de construction de l’usine de Longlaville, dans le cadre d’un financement de projet, avec pour objectif un démarrage de production à horizon S1 2028. Carbios dispose d’ [...]
Major Shareholder Announcement
30/03/2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis [...]
Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant
30/03/2026
Carbios confirms its objective for the Longlaville plant construction project, within a project financing framework and a target of starting production by H1 2028. Carbios has a solid cash position, with around €60 [...]
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
30/03/2026
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of [...]
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
30/03/2026
Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned [...]
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
30/03/2026
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 NOVATO, Calif., March 30, 2026 (GLOBE [...]
HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors
30/03/2026
DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in [...]

Pages